Aspirin/omeprazole 650/20

Drug Profile

Aspirin/omeprazole 650/20

Alternative Names: Aspirin/omeprazole 650mg/20mg; OA-65020; Omeprazole/aspirin 20/650; PA-65020

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator POZEN
  • Developer Aralez Pharmaceuticals Inc.
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antipyretics; Antirheumatics; Antiulcers; Benzimidazoles; Gastric antisecretories; Non-opioid analgesics; Salicylates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Pain in USA (PO, Tablet)
  • 07 Dec 2012 Phase-I development is ongoing in USA
  • 01 Oct 2012 Aspirin/omeprazole 650/20 is available for licensing as of 01 Oct 2012. http://www.pozen.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top